Compare Viatris Inc (VTRS) vs Teucrium Wheat Fund (WEAT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Teucrium Wheat Fund — how do they compare? Viatris Inc trades at $17.54 (market cap $19.79B), while Teucrium Wheat Fund trades at $25.21. The key difference: Viatris Inc pays a 2.83% dividend while Teucrium Wheat Fund pays none. Which is the better fit depends on your goals.
| VTRS | WEAT | |
|---|---|---|
Market Cap | $19.79B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $17.39 | $25.49 |
52-Week Low | $8.74 | $19.88 |
Enterprise Value | $32.00B | — |
Dividend Yield | 2.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
WEAT, the Teucrium Wheat Fund ETF, trades at $24.99, down 1.03% on the day, yet maintains a strong bullish technical trend with moving averages signaling buy. The fund has surged approximately 25% year-to-date, driven by wheat price increases and supply concerns highlighted by recent USDA production cuts. However, oscillators indicate potential short-term overbought conditions with RSI readings above 80.
The outlook for WEAT remains positive given fundamental agricultural supply constraints and inflation trends, but faces risks from potential price corrections after rapid gains and broader commodity market volatility. Investment appeal hinges on continued wheat market strength, though current technical indicators suggest caution for near-term entry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Teucrium Wheat Fund
WEAT is a commodity ETF that provides exposure to the price of wheat futures. It employs a laddered strategy across multiple benchmark contracts to mitigate the effects of contango and roll costs inherent in agricultural futures trading.
Read more on WEAT →
